Evidence · idea-005

CPT 95800, 95801, and 95806 exist and describe unattended home sleep studies distinguished by which channels are recorded

CPT 95782 and 95783 exist and describe attended polysomnography in patients younger than 6 years

Registered clinical trials exist evaluating home sleep apnea testing in children and adolescents, including ClinicalTrials.gov NCT03748771 ("Validation of ApneaLink Air Home Sleep Testing in the Diagnosis of Obstructive Sleep Apnea in Adolescent Children") and NCT05382754 ("Home Apnea Testing in CHildren Trial")

TAM component 1 — annual US volume of attended pediatric polysomnography, measured as claims volume for the pediatric PSG codes

TAM component 2 — realistic net price per pediatric home test to the ordering practice or sleep lab, assumed by the Generator at $150-$300 per study including scoring

TAM component 3 — addressable share assumption: the initial obtainable segment is children referred for suspected OSA who currently wait for an in-lab pediatric bed, assumed at 30-50% of pediatric PSG referral volume

Payer coverage claim — commercial and Medicaid medical policies generally do not cover home sleep apnea testing in patients under 18, restricting HSAT to adults

Conditional structure of the reimbursement claim, stated separately because it is what actually matters: if the coverage exclusion above is real and if it is written as an age restriction rather than a device-clearance restriction, then FDA clearance alone does not unlock payment and a policy-change campaign is a second, serial go-to-market cost

Moat lever — the defensible asset is the pediatric concurrent-PSG validation dataset and the pediatric scoring algorithm derived from it, plus the cleared pediatric indication itself, since a payer persuaded to cover pediatric HSAT will likely condition coverage on a device cleared for that age range

Mechanism and clinical risk — the dominant risk is false negatives. Pediatric OSA presents with lower AHI, more partial obstruction and arousal-based events than adult OSA, and an unattended cannula-and-belt montage without EEG cannot see arousals or normalise by true sleep time

Capital intensity and time-to-revenue — the dominant cost is a prospective multi-site validation study with concurrent in-lab PSG as reference standard in several hundred children, which the Generator estimates at mid-single-digit millions and 2-4 years before first revenue

Competitive intensity — the adult HSAT incumbents (ResMed, ZOLL/Itamar, Philips) hold cleared platforms that are one validation study away from this indication, so the competitive question is not whether they can follow but whether the pediatric segment is large enough for them to bother

Assumption, not a fact: the idea depends on pediatric sleep physicians accepting an unattended study as sufficient for a tonsillectomy decision in an otherwise-healthy child. There is no connector for clinician acceptance and no primary research behind this belief; if specialists continue to require in-lab PSG before surgery, a cleared and covered device still has no referral flow

Children referred for suspected obstructive sleep apnea wait long enough for an in-lab pediatric bed that families would accept a home study instead

A child aged 5 through 17 will tolerate a nasal cannula, thermistor, effort belts and an oximeter probe overnight at home well enough to produce a scorable study on the first attempt, at a failure rate comparable to adult home testing

A parent can apply and troubleshoot the full montage on their own child without a technician present

Otolaryngologists will accept an unattended home study as sufficient basis for an adenotonsillectomy decision in an otherwise-healthy child

A commercial or Medicaid payer will change a pediatric home-sleep-testing coverage policy on the strength of a cleared pediatric indication plus a published concurrent-PSG validation study

The pediatric segment is large enough to justify a dedicated device rather than an indication extension by an adult home-sleep-testing incumbent

A pediatric home study at the assumed price is cheaper to the payer than in-lab pediatric polysomnography by a margin large enough to motivate a policy change

An unattended montage without EEG can reproduce pediatric AHI thresholds to a level of agreement with concurrent in-lab polysomnography that a pediatric sleep physician would accept for a treatment decision

Effort belts, airflow sensors and oximetry probes can be sized and fitted across the 5-to-17 age range without fragmenting into separate device configurations

Pulse oximetry on a sleeping child at home achieves signal quality sufficient for event scoring despite motion artifact

No live, enforceable US patent blocks a pediatric-indicated unattended multi-channel home sleep recorder or the pediatric scoring algorithm applied to its output

Parents would prefer a home sleep apnea test to an in-lab polysomnography study for their child — unanswerable directly; the nearest revealed-behaviour twin found is claim 38 (a non-US pediatric adenotonsillectomy cohort's referral-to-consultation and referral-to-surgery delays), which quantifies the burden of the in-lab pathway but not any preference for or uptake of a home alternative. A US-specific PSG no-show, cancellation, or dropout rate was searched for directly this pass and not found (not merely not searched)